¼¼°èÀÇ ¸é¿ªÁ¾¾çÇÐ ½ÃÀå : À¯Çü, ÀûÀÀÁõ, ÃÖÁ¾ »ç¿ëÀÚº° ¿¹Ãø(2025-2030³â)
Immuno-Oncology Market by Type (Cancer Vaccines, Checkpoint Inhibitors, Cytokines), Indication (Breast Cancer, Colorectal Cancer, Lung Cancer), End-Users - Global Forecast 2025-2030
»óǰÄÚµå : 1591980
¸®¼­Ä¡»ç : 360iResearch Private Limited
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 191 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,939 £Ü 5,699,000
PDF, Excel & 1 Year Online Access (Single User License) help
PDF ¹× Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 4,249 £Ü 6,147,000
PDF, Excel & 1 Year Online Access (2-5 User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿Àϱâ¾÷ ³» 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 5,759 £Ü 8,332,000
PDF, Excel & 1 Year Online Access (Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ Áö¿ª »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 6,969 £Ü 10,083,000
PDF, Excel & 1 Year Online Access (Enterprise User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¸é¿ªÁ¾¾çÇÐ ½ÃÀåÀº 2023³â¿¡ 53¾ï 6,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 58¾ï 9,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 9.99%·Î ¼ºÀåÇØ 2030³â¿¡´Â 104¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸é¿ªÁ¾¾çÇÐÀº ¾Ï°ú ½Î¿ì±â À§ÇØ ½ÅüÀÇ ¸é¿ª½Ã½ºÅÛÀ» Ȱ¿ëÇÏ´Â °Í¿¡ ÃÊÁ¡À» ¸ÂÃá ±Þ¼ÓÈ÷ Áøº¸Çϰí ÀÖ´Â ºÐ¾ßÀÔ´Ï´Ù. ȯÀÚÀÇ »ýÁ¸À² QOLÀÇ Çâ»óÀ» ¸ñÀûÀ¸·Î ÇÑ ´Ù¾çÇÑ Ä¡·á¹ýÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. Ä¡·áÀÇ ÇѰè ÀÌ ºÐ¾ß´Â ¾Ï¼¼Æ÷¿¡ ´ëÇØ ƯÀÌÀûÀ¸·Î ¸é¿ª ¹ÝÀÀÀ» Ȱ¼ºÈ­Çϴ ǥÀû °³ÀÔÀ» Á¦°øÇÏ´Â °ÍÀ» ¸ñÀûÀ¸·Î Çϸç, ¾Ï Ä¡·áÀÇ À¯¸ÁÇÑ ´ëü ¼ö´ÜÀ» Á¦°øÇÏ´Â °ÍÀÔ´Ï´Ù. ¸é¿ªÁ¾¾çÇÐÀÇ ÀÀ¿ë¹üÀ§´Â Èæ»öÁ¾, Æó¾Ï, ´ëÀå¾Ï µî ´Ù¾çÇÑ ¾ÏÁ¾ÀÇ Ä¡·áºÎÅÍ È¿°ú¸¦ ³ôÀÌ´Â º´¿ë ¿ä¹ý±îÁö ´Ù¾çÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 53¾ï 6,000¸¸ ´Þ·¯
¿¹Ãø³â(2024) 58¾ï 9,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 104¾ï 5,000¸¸ ´Þ·¯
CAGR(%) 9.99%

¸é¿ªÁ¾¾çÇÐ ½ÃÀåÀº ¾Ï ÀÌȯÀ² Áõ°¡, »ý¸í°øÇÐÀÇ Áøº¸, Á¾¾ç ¸é¿ªÇÐÀÇ ÀÌÇØ Çâ»ó µîÀÇ ¿äÀÎÀÇ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀåÀ» ´õ¿í µÞ¹ÞħÇÕ´Ï´Ù. ±×·¯³ª °í¾×ÀÇ Ä¡·áºñ, º¹ÀâÇÑ ±ÔÁ¦ °æ·Î, ƯÁ¤ ¾Ï¿¡¼­ÀÇ Á¦ÇÑÀûÀΠȯÀÚ ¹ÝÀÀ°ú °°Àº °úÁ¦°¡ Å« Àå¾Ö ÀÌ·¯ÇÑ °úÁ¦¿¡µµ ºÒ±¸Çϰí, ÀÌ ºÐ¾ß¿¡¼­´Â ƯÈ÷ ȯÀÚÃþº°È­¸¦ À§ÇÑ ½Å±Ô ¹ÙÀÌ¿À¸¶Ä¿ÀÇ °³¹ß, º´¿ë¿ä¹ýÀÇ È¿´É Çâ»ó, ¼¼Æ÷¿ä¹ýÀÇ Àû¿ë È®´ë µî À¯¸®ÇÑ ºñÁî´Ï½º ±âȸ ÀÌÁß Æ¯À̼º Ç×üÀÇ Å½»ö, T¼¼Æ÷¿ä¹ýÀÇ È¿´É Çâ»ó, â¾à°ú ¾àÁ¦ °³¹ß¿¡ AI¸¦ Ȱ¿ëÇÏ´Â µîÀÇ Çõ½ÅÀûÀÎ ±â¼úÀÌ ³ÑÃijª°í ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ ±âȸ¸¦ Æ÷ÂøÇϱâ À§ÇØ ÀÌÇØ °ü°èÀÚ´Â °øµ¿ ¿¬±¸, »ý¸í °øÇÐ ±â¾÷°úÀÇ Àü·«Àû Á¦ÈÞ, ½Å±â¼ú ÅõÀÚ¿¡ ÁÖ·ÂÇØ¾ßÇÕ´Ï´Ù. ¾×¼¼½º °³¼±µµ ¿©ÀüÈ÷ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¿ªÇÐÀº ¿ªµ¿ÀûÀÌ°í °æÀïÀÌ Ä¡¿­ÇÏ°í ±Þ¼ÓÇÑ ±â¼ú Áøº¸¿Í ÀÓ»ó½ÃÇèÀÇ Á߽ø¦ Ư¡À¸·Î Çϰí ÀÖ½À´Ï´Ù. ÅëÂû°ú ½ÃÀå ¼ö¿ä¿¡ ´ëÇÑ Àü·«Àû ÀûÀÀÀÌ ÇʼöÀûÀÔ´Ï´Ù.

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ¸é¿ªÁ¾¾çÇÐ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®ÀÇ ÇØ¸í

¸é¿ªÁ¾¾çÇÐ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ ¾ò´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ½°ú µ¿½Ã¿¡ ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

Portre's Five Forces: ¸é¿ªÁ¾¾çÇÐ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ ¿öÅ©´Â ¸é¿ª Á¾¾ç ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ´ç½ÅÀº ´õ °­ÀÎÇÑ ½ÃÀå¿¡¼­ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¸é¿ªÁ¾¾çÇÐ ½ÃÀå¿¡¼­ ¿ÜºÎ·ÎºÎÅÍÀÇ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¸é¿ª Á¾¾ç ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹ÃøÇÒ ¼ö ÀÖ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ°¡ µÇ¾ú½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ¸é¿ª Á¾¾çÇÐ ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

¸é¿ªÁ¾¾çÇÐ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. °ø°³ ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õ´Â °æÀïÀÌ Ä¡¿­ÇØÁö¸é¼­ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» Çϱâ À§ÇØ ÇÊ¿äÇÑ Áö°ß ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : ¸é¿ª Á¾¾çÇÐ ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¸é¿ªÁ¾¾çÇÐ ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡Çϱâ À§ÇÑ Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ¿¡ µû¶ó °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ºÐÇÒÇϰí Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× ±ÇÀå : ¸é¿ªÁ¾¾çÇÐ ½ÃÀå¿¡¼­ ¼º°øÀ» À§ÇÑ ±æÀ» ±×¸®±â

¸é¿ªÁ¾¾çÇÐ ½ÃÀåÀÇ Àü·«ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ: ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­: ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

Á¦6Àå ¸é¿ªÁ¾¾çÇÐ ½ÃÀå : À¯Çüº°

Á¦7Àå ¸é¿ªÁ¾¾çÇÐ ½ÃÀå : ÀûÀÀÁõº°

Á¦8Àå ¸é¿ªÁ¾¾çÇÐ ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ ¸é¿ªÁ¾¾çÇÐ ½ÃÀå

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¸é¿ªÁ¾¾çÇÐ ½ÃÀå

Á¦11Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¸é¿ªÁ¾¾çÇÐ ½ÃÀå

Á¦12Àå °æÀï ±¸µµ

±â¾÷ ¸ñ·Ï

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Immuno-Oncology Market was valued at USD 5.36 billion in 2023, expected to reach USD 5.89 billion in 2024, and is projected to grow at a CAGR of 9.99%, to USD 10.45 billion by 2030.

Immuno-oncology is a rapidly advancing field focusing on harnessing the body's immune system to fight cancer. Its scope involves various therapies, such as immune checkpoint inhibitors, cancer vaccines, and cell therapies, which aim to improve survival rates and quality of life for cancer patients. The necessity of immuno-oncology stems from the limitations of traditional cancer therapies, such as chemotherapy, which often result in severe side effects and limited efficacy in controlling the disease. This field aims to provide targeted interventions that activate an immune response specifically against cancer cells, offering a promising alternative for cancer treatment. Applications of immuno-oncology span from treating various cancer types, including melanoma, lung, and colorectal cancers, to combination therapies that enhance effectiveness. The end-use scope primarily targets hospitals, cancer research centers, and specialized clinics.

KEY MARKET STATISTICS
Base Year [2023] USD 5.36 billion
Estimated Year [2024] USD 5.89 billion
Forecast Year [2030] USD 10.45 billion
CAGR (%) 9.99%

The market for immuno-oncology is influenced by factors such as increased cancer prevalence, advancements in biotechnology, and improved understanding of tumor immunology. The rising demand for personalized medicine and the ongoing focus on R&D further propel market growth. However, challenges such as high treatment costs, complex regulatory pathways, and limited patient response in certain cancers pose significant hurdles. Despite these challenges, the field presents lucrative opportunities, particularly in developing novel biomarkers for patient stratification, enhancing the efficacy of combinatory therapies, and expanding the application of cell therapies. Innovations abound in exploring bispecific antibodies, enhancing T-cell therapy effectiveness, and leveraging AI for drug discovery and development.

To seize these opportunities, stakeholders should focus on collaborative research efforts, strategic partnerships with biotechnology firms, and investments in emerging technologies. Additionally, addressing cost-related challenges and improving patient access to therapies remain crucial. The nature of the immuno-oncology market is dynamic and highly competitive, characterized by rapid technological advancements and a strong emphasis on clinical trials. Continued innovation and strategic adaptation to evolving scientific insights and market demands are essential for sustained growth and success in this transformative field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Immuno-Oncology Market

The Immuno-Oncology Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Porter's Five Forces: A Strategic Tool for Navigating the Immuno-Oncology Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Immuno-Oncology Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Immuno-Oncology Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Immuno-Oncology Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Immuno-Oncology Market

A detailed market share analysis in the Immuno-Oncology Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Immuno-Oncology Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Immuno-Oncology Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Immuno-Oncology Market

A strategic analysis of the Immuno-Oncology Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Immuno-Oncology Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adaptimmune Therapeutics PLC, Adicet Bio, Inc., Agilent Technologies, Inc., Allogene Therapeutics, Amgen Inc., Arcus Biosciences, Inc., Asher Biotherapeutics, Inc., Astellas Pharma Inc., AstraZeneca PLC, Atara Biotherapeutics, Inc., Autolus Therapeutics PLC, Avantor, Inc., BeiGene, Inc., Bio-Rad Laboratories, Inc., BioNTech SE, Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Cellectis SA, F. Hoffmann-La Roche AG, Fate Therapeutics Inc., Merck KGaA, Sanofi S.A., Thermo Fisher Scientific Inc., and Triumvira Immunologics Inc..

Market Segmentation & Coverage

This research report categorizes the Immuno-Oncology Market to forecast the revenues and analyze trends in each of the following sub-markets:

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. Immuno-Oncology Market, by Type

7. Immuno-Oncology Market, by Indication

8. Immuno-Oncology Market, by End-Users

9. Americas Immuno-Oncology Market

10. Asia-Pacific Immuno-Oncology Market

11. Europe, Middle East & Africa Immuno-Oncology Market

12. Competitive Landscape

Companies Mentioned

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â